

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
	Applicant Bastian Nuyen et al.		
	Filing Date May 10, 2002	Group Art Unit 1655	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US 2001/0021380	09/13/01	Pluenneke			
	AB	US 2002/0098185	07/25/02	Sims et al.			
	AC	US 2003/0044893	03/06/03	Baum et al.			
	AD						
	AE						
	AF						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AG	WO 98/01352	01/15/98	WIPO				
	AH							
	AI							
	AJ							
	AK							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AL	Mitsiades et al., "Pre-clinical studies in support of the clinical developments of Aplidin® (APL) for the treatment of multiple myeloma (MM)", Blood, November 16, 2003, vol. 102, no. 11, page 74a, abstract #250
	AM	U.S. National Cancer Institute, U.S. National Institutes of Health, www.cancer.gov, "Cancer Topics – Colon and Rectal Cancer", http://www.cancer.gov/cancertopics/types/colon-rectal , 2 pages
	AN	U.S. National Cancer Institute, U.S. National Institutes of Health, www.cancer.gov., "Gastric Cancer (PDQ®): Treatment – General Information About Gastric Cancer", http://www.cancer.gov/cancertopics/pdq/treatment/gastric/patient , 4 pages
	AO	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	